LEAPChem Has Finasteride (98319-26-7) Now
Nov. 2019/3/6 16:03:02 By LEAP Chem
LEAPChem - Pharmaceutical Chemicals is a premier supplier of pharmaceutical chemicals and other chemical raw materials for global customers including drug manufacturers, universities, research labs, R&D centers, and other industries that use chemical raw materials such as polymers, textiles, agriculture, coatings, etc. As an ISO 9001:2015 certified company, our team of experts in customer service, product sourcing, logistics, regulatory and compliance operate at the highest standard. LEAPChem's experienced sales team will work tirelessly to find the chemicals you need for a price you can afford. LEAPChem - Pharmaceutical Chemicals is happy to highlight Finasteride, a very promising chemical in the global chemical market.
Basic Information of Finasteride
Chemical Name: Finasteride
Cas No.: 98319-26-7
Molecular Formula: C23H36N2O2
Finasteride, sold under the brand names Proscar and Propecia among others, is a medication used mainly to treat an enlarged prostate or hair loss in men. It can also be used to treat excessive hair growth in women and as a part of hormone therapy for transgender women. It is taken by mouth.
Side effects are generally mild. Some men experience sexual dysfunction, depression, anxiety, or breast enlargement. It may also increase the risk of certain forms of prostate cancer. Finasteride is a 5α-reductase inhibitor, and therefore an antiandrogen. It works by decreasing the production of dihydrotestosterone (DHT) by about 70%, including in the prostate gland and the scalp.
Physicians sometimes prescribe finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate.
Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with finasteride may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies finasteride but not alpha-1 inhibitors reduce the risk of acute urinary retention (?57% at 4 years) and the need for surgery (?54% at 4 years). If the drug is discontinued, any therapeutic benefits are reversed within about 6–8 months.
A 2010 Cochrane review found a 25 or 26% reduction in the risk of developing prostate cancer with 5α-reductase inhibitor chemoprevention. A followup study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests a significant reduction in prostate cancer risk is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. In addition, there is no negative impact of 5-α-reductase inhibitor on survival rates of people with prostate cancer.
Finasteride is also used to treat male pattern baldness (androgenetic alopecia) in men, a condition that develops in up to 80% of Caucasian men.
In the United States, finasteride and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017.
Treatment with finasteride slows further hair loss and provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken. Taking finasteride leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT, finasteride can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle. Finasteride is most effective on the vertex but can reduce hair loss in all areas of the scalp. Finasteride has also been tested for pattern hair loss in women; however, the results were no better than placebo.
Finasteride is a 5α-reductase inhibitor. It is specifically a selective inhibitor of the type II and III isoforms of the enzyme. By inhibiting these two isozymes of 5α-reductase, finasteride reduces the formation of the potent androgen dihydrotestosterone (DHT) from its precursor testosterone in certain tissues in the body such as the prostate gland, skin, and hair follicles. As such, finasteride is a type of antiandrogen, or more specifically, an androgen synthesis inhibitor. However, some authors do not define finasteride as an "antiandrogen".
LEAPChem combines experience and expertise in the distribution of hazardous and non-hazardous raw materials to its professional customer base. Working alongside an elite network of manufacturers, carriers and warehouses, we are equipped to deliver your product safely and efficiently, throughout every step of the supply chain.
If you are interested in Finasteride, click here to send an inquiry!
Make LEAPChem your pharmaceutical chemicals long-term partner and contact us today!